Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials by Vrinten, C et al.
Ephedrine as add-on therapy for
patients with myasthenia gravis:
protocol for a series of randomised,
placebo-controlled n-of-1 trials
Charlotte Vrinten,1,2 Alexander F Lipka,3 Erik W van Zwet,4 Kirsten J M Schimmel,5
Martina C Cornel,2 Marja R Kuijpers,6 Yechiel A Hekster,7 Stephanie S Weinreich,2
Jan J G M Verschuuren3
To cite: Vrinten C, Lipka AF,
van Zwet EW, et al. Ephedrine
as add-on therapy for
patients with myasthenia
gravis: protocol for a series
of randomised, placebo-
controlled n-of-1 trials. BMJ
Open 2015;5:e007863.
doi:10.1136/bmjopen-2015-
007863
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-007863).
Received 4 February 2015
Revised 8 April 2015
Accepted 12 April 2015
For numbered affiliations see
end of article.
Correspondence to
Charlotte Vrinten;
c.vrinten@ucl.ac.uk
ABSTRACT
Introduction: Myasthenia gravis (MG), a rare
neuromuscular disease, is often initially treated using
acetylcholinesterase inhibitors. Patients who do not
respond adequately depend on the use of
corticosteroids or other immunosuppressive
medication, but these may have serious side effects.
Clinical observations suggest that ephedrine can
diminish, postpone or even prevent the need for
immunosuppressive therapy when added to
acetylcholinesterase inhibitors or low-dose prednisone.
In the Netherlands, ephedrine is not licensed for MG nor
is reimbursement guaranteed. MG is a rare condition,
and ephedrine might be indicated only in a subset of
patients. Thus, randomised controlled trials comparing
large groups are difficult to conduct. We, therefore, aim
to aggregate data from a small series of n-of-1
trials (also known as single patient trials) to assess the
effect of ephedrine as add-on treatment for MG.
Methods and analysis: Single-centre, placebo-
controlled, double-blind, randomised, multiple
crossover n-of-1 studies in 4 adult patients with
generalised MG who show inadequate improvement on
pyridostigmine and/or immunosuppressive drugs. Each
n-of-1 trial has 3 cycles of two 5-day intervention
periods. Treatment: 25 mg ephedrine or placebo, twice
daily. Main outcome measure: Quantitative Myasthenia
Gravis (QMG) test. Statistical analysis: fixed effects
linear model for QMG for all patients combined.
Secondary outcome measures: Clinical: effects on MG-
Composite and MG-Activities of Daily Living (MG-ADL)
scales; QMG at individual level; adverse events.
Acceptability of trial design: number of patients eligible
and enrolled; number of treatment cycles completed;
patients’ and caregivers’ experiences.
Ethics and dissemination: This study was approved
by the Medical Ethics Committee of Leiden University
Medical Center, No. P14.108. Results of the trial will be
reported in a peer-reviewed publication. Regulatory
stakeholders will comment on the suitability of the trial
for market authorisation and reimbursement purposes.
Trial registration number: This study is registered
under EudraCT number 2014-001355-23, protocol no.
40960, V.1.0, registration date 27 March 2014.
INTRODUCTION
Myasthenia gravis (MG) is an autoimmune
disorder in which antibodies are directed
against components of the neuromuscular
junction, resulting in an impairment of
neuromuscular transmission. MG is a rare
disorder, with a prevalence of about 78 per
million1–3 and an incidence of 4–6 per
million.3 4 Clinically, MG is characterised by
ﬂuctuating muscle weakness in various
muscle groups and fatigability, often resulting
in marked impairment in activities of daily
living (ADL). Muscle weakness and fatigabil-
ity are often more pronounced at the end of
the day, after exercise, during warm weather
or during illness.5–8
Many patients respond well to ﬁrst-line treat-
ment with acetylcholinesterase inhibitors
(AChEIs), such as pyridostigmine, which
inhibit the activity of the enzyme that breaks
down the neurotransmitter acetylcholine and
thus, enhances neuromuscular transmission.6 9
This treatment is well tolerated by most
patients. If symptoms can no longer be con-
trolled with AChEIs, the second step in MG
treatment consists of immunosuppression with
high doses of corticosteroids (prednisone),
azathioprine, or other immunosuppressant
Strengths and limitations of this study
▪ Series of prospective, randomised, placebo-
controlled trials for a rare disease.
▪ ‘Level 1’ evidence of add-on treatment effect of
ephedrine in myasthenia gravis.
▪ Optional, 6-month open-label extension phase
after prospective trial.
▪ Harms and benefits assessed, as well as accept-
ability of this type of trial.
▪ Potential limitations include limited generalisabil-
ity due to small sample size.
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agents;6 9 however, these can give rise to moderate or
serious side effects.
Anecdotal evidence and our clinical observations
suggest that some patients with MG can avoid high-dose
immunosuppressive treatment by using ephedrine as
add-on treatment to AChEIs or low doses of prednisone.
Ephedrine is a sympathomimetic agent which acts on the
adrenergic receptors.10 Its mechanism of action in MG
has been investigated,11–14 but is not well understood.15 16
One study showed that ephedrine increases the quantal
content of the endplate potential as well as the probabil-
ity of quantal release of acetylcholine in an in vitro
canine model, but only at concentrations that would not
be reached in patients.14 Another study suggested that
ephedrine improves neuromuscular transmission by
stimulating β2-adrenergic receptors and stabilising the
structure of the neuromuscular junction.16 Clinically, the
onset of the effect is usually seen within hours to days,
although some studies in congenital MG suggest that it
may take weeks to months before the full effect is
reached in some patients.17 18 The effects of ephedrine
in patients with MG have not been studied extensively,19
but it appears to be well tolerated (personal observations
by JJGMV). Side effects consist of adrenergic effects, such
as palpitations, restlessness, insomnia, headache and
nausea, which are most likely dose dependent.19
Rationale for the trial
Although anecdotal evidence20–22 and our clinical obser-
vations suggest that some patients with MG may beneﬁt
from ephedrine, a recent Cochrane systematic review
showed that its effects have never been formally assessed
in randomised controlled, clinical trials (RCTs).19 This
lack of evidence hinders market approval of ephedrine
for MG and may also hinder its reimbursement.
MG is a rare disease, and there are only a small
number of patients who might beneﬁt from add-on
treatment with ephedrine. It is, therefore, difﬁcult to
conduct group-RCTs to determine its effectiveness.
N-of-1 trials (also known as single patient trials or n-of-1
RCTs) may provide a way of gathering scientiﬁcally
robust evidence of effectiveness in small patient groups.
N-of-1 trials are randomised, controlled, multiple cross-
over trials in single patients, in which data are contribu-
ted over several treatment cycles. Evidence from several
n-of-1 trials can be aggregated to produce population
treatment effect estimates.23–25 Given the multiple cross-
over character of n-of-1 trials (ie, each patient acts as
their own control and contributes multiple cycles of
data), the number of patients needed in n-of-1 trials
(ie, sample size) to estimate the population treatment
effect is much reduced compared with group-RCTs26
and thus makes this type of trial very suitable to conduct
research in small patient populations.27 28
Aim and objectives
We aim to conduct a series of n-of-1 trials to obtain scien-
tiﬁcally robust (‘level 1’) evidence29 of beneﬁts and
harms of add-on treatment with ephedrine for auto-
immune MG, followed by an optional open-label exten-
sion phase for patients who decide to continue treatment
with ephedrine. The primary endpoint is the study popu-
lation treatment effect of ephedrine compared with
placebo on muscle strength and endurance, as measured
by the Quantitative Myasthenia Gravis (QMG) score,
when ephedrine is added to regular treatment with pyri-
dostigmine, either alone or in combination with stable
low-dose prednisone or immunosuppressive treatment.
Key secondary objectives include:
▸ Describing the effects of add-on treatment with ephe-
drine on secondary outcome measures, including the
MG-Composite30 31 and MG-Activities of Daily Living
(MG-ADL);32
▸ Determining the effect of add-on treatment with
ephedrine for each patient individually;
▸ Recording any adverse effects of add-on treatment
with ephedrine.
Other secondary objectives include:
▸ Evaluating the acceptability of the trial design by
exploring the perspectives of patients, physicians, and
pharmacists on the use of n-of-1 trials, and by record-
ing the number of people eligible for the study, the
number of people who enrol, complete the multiple
crossover phase of the trial, and elect to continue
treatment with ephedrine during the open-label
extension phase;
▸ Comparing immediate and long-term effects of ephe-
drine (for patients participating in the open-label extension
phase).
Until now, n-of-1 trials have generally been conducted
to guide individual therapeutic decisions.33 34 The
current series of trials is part of a project which aims to
create more knowledge about the suitability of n-of-1
trials for regulatory decisions such as reimbursement
and marketing authorisation. Regulatory and patient sta-
keholders were, therefore, consulted on the design of
the protocol, and both will contribute to dissemination
of trial results (see ‘Dissemination of results’ and
‘Discussion’ sections).
In addition, theoretical and actual beneﬁts and
burdens for n-of-1 trial participants have been described
for more common disorders such as osteoarthritis and
Attention Deﬁcit Hyperactivity Disorder (ADHD).33–36
This study will explore whether beneﬁts and burdens of
n-of-1 trials conducted for rare diseases (where there are
often fewer treatment options available) are similar to
those for more common diseases. The experiences of
physicians and pharmacists involved in the trial will be
compared with experiences of their counterparts in a
routine n-of-1 trial service in Australia.35
METHODS AND ANALYSIS
Study design and duration
The study consists of a small series of n-of-1 trials fol-
lowed by an optional open-label extension phase. Each
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n-of-1 trial is a randomised, placebo-controlled,
physician-blinded and patient-blinded, multiple cross-
over trial in a single patient. The n-of-1 trials will consist
of three cycles of 2 weeks duration, each consisting of
one period of ephedrine treatment and one period of
placebo treatment. The order of the treatment periods
will be randomised. This 6-week multiple crossover
phase will be followed by a 4-week evaluation phase,
during which data analysis of the multiple crossover
phase, feedback of results to the patient and their treat-
ing physician, and evaluation of the trial will take place.
Thus, each n-of-1 trial will take 10 weeks to complete.
The optional open-label extension phase which follows
the n-of-1 trial will be a further 6 months. The design of
the trial is presented in ﬁgure 1.
Study setting
The ﬁrst doses of the two periods of the ﬁrst cycle will
be administered during an inpatient visit. All clinical
measures and tests (eg, QMG, ECG, blood tests) will be
performed during outpatient visits. All other study medi-
cation as well as self-report questionnaire measures will
be administered in the home setting. The 6-month
open-label extension phase will be conducted in the
home setting, with outpatient follow-up visits at 2, 4 and
6 months.
Study population
Adult patients with generalised autoimmune MG, who
are being treated at Leiden University Medical Center
(LUMC). Inclusion and exclusion criteria are described
in box 1.
Sample size
The QMG test results in a numerical score between 0
and 39, with higher scores indicating more severe
disease. The estimated SD of repeated measures for a
single person is 2.95 based on our clinical observations
and an earlier trial.37 An average decrease in QMG
score of 3.5 points is considered clinically relevant.38 39
A linear model with ﬁxed effects for treatment and
patient will be ﬁtted to the repeated QMG measure-
ments. Our sample size computations are based on the
test of signiﬁcance of the treatment effect in this model
(see ‘Analysis’ section). Monte Carlo simulations were
used to compute the power with three cycles (ie, 6 mea-
surements) per patient for 3, 4, and 5 patients, which
was 0.648, 0.772 and 0.862, respectively. In light of the
availability of eligible patients, time and resources, we
chose a sample size of 4 patients, achieving approxi-
mately 77% power.
Blinding, treatment allocation, and randomisation
Patients and physicians will be blinded to the treatment
sequence during the multiple crossover phase of the
n-of-1 trial. Randomisation will be carried out for each
individual n-of-1 trial by the dispensing hospital phar-
macy to ensure patient and physician blinding, and will
be performed in MS Excel. Ephedrine and placebo
treatments will be randomised in a 1:1 ratio per cycle
over the three cycles of the n-of-1 trial (eg, AB-BA-BA).
Unblinding will occur when a participant has completed
the multiple crossover phase of the trial or in the case of
a serious adverse event (SAE) which cannot be treated
without knowing which treatment the patient was receiv-
ing (see also ‘Safety Evaluation’ section).
Interventions and dosing schedule
During the entire trial, treatment with pyridostigmine,
low-dose prednisone and steroid-sparing drugs, such as
azathioprine, will be continued by the patient according
to their prestudy treatment schedule. For the n-of-1 trial,
oral add-on treatment with ephedrine 25 mg twice daily
will be compared with add-on treatment with a placebo
twice daily. To this purpose, commercial tablets of 50 mg
ephedrine will be divided into two equal halves, and
repackaged in a non-transparent capsule. For the
placebo, a placebo tablet will be repackaged in a non-
transparent capsule. The divided 50 mg commercial
tablets comply with the European Pharmacopoeia (Ph.
Eur.) test for uniformity of mass for subdivided parts.
For the open-label extension phase, the ephedrine
tablets will be administered as such.
Any medication for coexisting conditions will be con-
tinued as before the trial, as well as any other interven-
tions aimed at improving symptoms of MG (eg, physical
therapy). Accountability will be assessed by the dispens-
ing pharmacy, who will maintain records of drugs dis-
pensed. Participant compliance will be assessed by the
physician who will ask participants to return all unused
study medication and will record pill count. Prednisone
and cholinesterase inhibitor dosing will be documented
as concomitant medication.
Rescue medication
The study protocol does not specify any rescue medica-
tion to treat side effects of ephedrine treatment because
in our experience these are usually mild at the dose
used in this study. In case of SAEs, the patient may be
withdrawn from the trial and appropriate treatment will
be started.
Trial procedures
Appropriately trained medical staff will carry out the
screening for inclusion and exclusion criteria, including
an ECG recording, and enrolment of participants into
the n-of-1 trials. Baseline QMG will be measured and a
standard neurological examination will be conducted.
To standardise QMG measurements, all assessments will
be conducted at a predeﬁned time-interval after the last
dose of study medication.
N-of-1 trial: multiple crossover phase and evaluation phase
The n-of-1 trial consists of a double-blinded multiple
crossover phase (weeks 1–6) and an evaluation phase
(weeks 7–10; see ﬁgure 1). The multiple crossover phase
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consists of three cycles with two 1-week treatment
periods: one period of 5 days (Monday–Friday) when
ephedrine is taken as add-on treatment, and one 5-day
period (Monday–Friday) when a placebo is taken. The
5-day treatment periods are followed by a 2-day wash-out
period (Saturday and Sunday) to prevent carry-over
effects. A 2-day wash-out is considered adequate because
of the short half-life of ephedrine of approximately 6 h.40
On the ﬁrst day of the ﬁrst two periods (cycle 1),
study medication will be administered in hospital to
monitor adverse reactions. Study medication will be
taken at home on all other days, with an outpatient hos-
pital visit at the end of each treatment period.
Treatment with pyridostigmine, low-dose prednisone or
steroid-sparing drugs will be continued as before the
trial, with a ﬁxed dosing schedule.
The QMG score will be assessed by a neurologist or
research nurse at baseline and during hospital visits at
the end of each treatment period. The QMG has often
been used in clinical trials and was recommended as
outcome measure for all prospective research in MG by
the Myasthenia Gravis Foundation of America
(MGFA).41 Secondary outcomes that will be measured
during this hospital visit include the MG-Composite30 31
and the MG-ADL32 to reﬂect recent recommendations
by the MGFA.42 The effect of blinding will also be
assessed during the hospital visit at the end of each
cycle by recording which treatment the patient and phys-
ician believed was administered during each period.
Potential adverse effects of ephedrine will be moni-
tored as follows: vital signs will be measured 30, 60 and
120 min after administration of study medication on the
ﬁrst day of periods 1 and 2. In addition, an ECG will be
recorded 60 min after medication is administered on
these days, and also during the hospital visit in weeks 1,
2 and 6. Screening blood tests (haematology, liver and
renal function tests) will be performed during hospital
visits in weeks 1, 2 and 6. Finally, a self-report symptom
questionnaire will measure adverse effects on the ﬁrst
day of periods 1 and 2, as well as on the second and
fourth day of every treatment period.
Following completion of the multiple crossover part of
the trial, the results of each n-of-1 trial will be analysed
by the researchers and a report will be drafted for each
patient individually (weeks 7 and 8). This report, which
will unblind patient and physician, will be made avail-
able to the treating physician to guide clinical decision-
making and to discuss with the patient during an
outpatient visit in week 8. The resulting treatment
decision will be recorded. In addition, the number of
eligible patients, patients recruited, patients who com-
pleted their n-of-1 trial, the total number of completed
Figure 1 Design of the study.
Treatment periods (A and B) will
be randomised. Figure not to
scale.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
▸ Adult patients with a diagnosis of generalised myasthenia
gravis (MG), based on clinical signs or symptoms suggestive
of generalised MG and confirmed by a positive serological test
for acetylcholine receptor (AChR) antibodies
▸ No adequate improvement of myasthenic symptoms with pyri-
dostigmine, either alone or in combination with low-dose
(maximum 15 mg/day) prednisone or other immunosuppres-
sive drugs
▸ Stable dosages of pyridostigmine, prednisone or other
immunosuppressive drugs for at least 6 weeks prior to trial
enrolment
Exclusion criteria
▸ Purely ocular myasthenia
▸ Ephedrine was not tolerated in the past or is contraindicated
due to myocardial ischaemia; cardiac arrhythmia; inherited
prolonged QT syndrome or prolonged QT interval; angle-
closure glaucoma; psychiatric treatment; hypertension; poorly
regulated diabetes; prostatic hypertrophy; thyrotoxicosis; or
relevant drug interactions (monoamine oxidase (MAO) inhibi-
tors, α and β blockers)
▸ Prednisone dose of >15 mg/day, recent (<3 months) or
regular intravenous immunoglobulin or plasma exchange
▸ Myasthenic crisis in the past 3 months
▸ Thymectomy in the past 6 months, or scheduled to take place
during the n-of-1 trial
▸ Inability to fill out the study questionnaires, be interviewed in
Dutch, undergo the trial’s test procedures, give informed
consent, or any other reason which renders the patient unsuit-
able to participate
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cycles, and the number of patients who decided to par-
ticipate in the open-label extension phase will be
recorded to evaluate the acceptability of this type of
trial.
In addition to the quantitative evaluation of the
acceptability of this type of trial, acceptability will also be
evaluated qualitatively by exploring the experiences of
patients, physicians and pharmacists in the trial.
Semistructured telephone interviews of approximately
30 min will be conducted with the patient (week 9 or
10). The topics for the interview schedule were derived
from methodological (theoretical) beneﬁts and burdens
of n-of-1 trials,24 published studies on experiences of
patients and carers with n-of-1 trials,33 35 and process-
related aspects of the trial at hand. The experiences of
physicians and pharmacists involved in the trial will be
explored quantitatively by registering the time they
spend on the trial, as well as qualitatively from attending
project meetings.
Optional open-label extension phase (months 3–8)
Participants who choose to enter the open-label exten-
sion phase will be followed up for 6 months to explore
the long-term effects of add-on treatment with ephe-
drine. This will include hospital visits at 2, 4, and
6 months as part of regular clinical care, during which a
standardised neurological examination, QMG,
MG-Composite, and MG-ADL will be assessed and any
adverse effects will be recorded.
Safety evaluation
Adverse events
Adverse events (AEs) and SAEs are deﬁned according to
the Dutch Medical Research Involving Human Subjects
Act 2006. AEs will be monitored throughout the n-of-1
trial. All SAEs and Suspected Unexpected Serious
Adverse Reactions (SUSARs) occurring during the study
and either reported spontaneously or as part of the AE
monitoring will be followed up by the principal investi-
gator and will be reported separately to the Medical
Ethics Committee (MEC). Unblinding will occur if there
is reason to believe a SAE or SUSAR was due to the
study medication and if the patient cannot be treated
without knowing which treatment they were receiving.
Unblinding and the reason for unblinding will be
recorded. All AEs, SAEs and SUSARs will be followed up
until they have abated or a stable situation has been
reached.
Removal from the trial and replacement of participants
Participants will be removed from the study if informed
consent is withdrawn. The investigator can decide to
withdraw a participant from the n-of-1 trial for urgent
medical reasons. Speciﬁc criteria for withdrawal of indi-
vidual participants consist of:
▸ The occurrence of a SAE or SUSAR;
▸ A myasthenic crisis or worsening of symptoms requir-
ing any treatment other than the trial medication;
▸ A need to undergo thymectomy before the end of a
cycle in the multiple crossover phase of the trial.
Participants who are withdrawn from the study will be
followed up until their planned end of the n-of-1 trial to
assess AEs of the trial medication. The cycles completed
before a participant’s withdrawal from the study will be
analysed as part of the trial. Participants who fail to com-
plete a single cycle of the multiple crossover phase will
be replaced.
Premature termination of the study
The study will be terminated prematurely if SAEs occur
that are deemed in all likelihood to be caused by the
trial medication.
Analysis
Effect of add-on ephedrine compared with placebo on
muscle strength and endurance for all patients
The average QMG scores for baseline, placebo and
ephedrine periods of the multiple crossover phase will
be described for all n-of-1 trials combined. A linear
model for QMG score with ﬁxed effects for treatment
and patient will be ﬁtted for all patients in the trial com-
bined. All treatment effects for the study population will
be tested at the 0.05 level.
If we can demonstrate a signiﬁcant treatment effect in
the study population, we conclude that, on average, ephe-
drine has an effect on the four patients enrolled in the
study. If this is the case, we will proceed to test if there is a
signiﬁcant treatment effect in the population from which
the four patients were sampled. To this end, we will ﬁt a
linear mixed model for QMG score with ﬁxed effects for
treatment and patient, and also a random treatment effect.
Effects on secondary outcome measures
For the secondary outcome measures, the average base-
line score and the average scores for the ephedrine and
placebo periods during the multiple crossover phase will
be described for all n-of-1 trials combined.
Effect of add-on treatment with ephedrine for each patient
individually
For each individual patient, QMG scores, scores for sec-
ondary outcome measures, and adverse effects reported
during the ephedrine and placebo periods will be
described in an individual patient report. This report
will be discussed by the patient and their physician
during the evaluation phase of the n-of-1 trial and may
be used to guide individual therapeutic decisions. All
data from completed cycles will be used for the analyses
of treatment effects. Given the small sample size, no
additional analyses at group level, such as interim or sub-
group analyses, are planned.
Adverse effects, study inclusion and views of patients,
physicians, and pharmacists
A descriptive report will list the number of patients who
experienced adverse effects during the placebo and
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ephedrine periods of the multiple crossover phase of
the n-of-1 trials, as well as the type of adverse effect. This
includes both self-reported adverse effects and those
measured by vital signs, ECG and blood test monitoring.
The number of patients eligible for the trial, as well as
the number of patients who enrolled in the trial, who
completed the trial, and who opted to proceed with the
open-label extension afterwards will be described. A
qualitative analysis will explore the experiences of
patients, physicians and pharmacists with the n-of-1 trial,
including patient satisfaction. This evaluation will also
include a description of the average time cost of the
n-of-1 trial for the physicians and pharmacists.
Long-term effects of ephedrine
Baseline QMG, MG-Composite and MG-ADL scores, and
the scores measured during the n-of-1 trials will be com-
pared with the scores for these measures during the
open-label extension phase at 2, 4 and 6 months.
ETHICS AND DISSEMINATION
Ethics approval
Any amendments to the study protocol will be recorded
and submitted to the MEC, with substantial amendments
submitted for approval prior to implementation. An
annual progress report, including information on the
date of inclusion of the ﬁrst participant; the total
number of participants who have been included and
completed the study; safety and AEs; and amendments
to the protocol will be submitted annually and within
3 months of the end of the study (or within 15 days if
the study is terminated prematurely). A ﬁnal study
report with its results and any publications or abstracts
of the study will be submitted to the MEC and the
Competent Authority within 1 year of the end of the
study. Since AEs are strictly monitored as outlined
earlier and the duration of blinding is only short
(6 weeks during the multiple crossover phase of the
n-of-1 trials), no additional data monitoring committee
will be implemented.
This study is registered under EudraCT number
2014-001355-23, protocol no. 40960, V.1.0, registration
date 27 March 2014. Registration details from the WHO
Trial Registration Data Set can be found in table 1. The
study will be conducted in accordance with the princi-
ples of the Declaration of Helsinki (2008) and in
accordance with the Dutch Medical Research Involving
Human Subjects Act and Good Clinical Practice
guidelines.
Recruitment and informed consent
Eligible patients will be recruited from the existing
patient population at the LUMC; this population from
which the sample will be drawn is expected to be large
enough to achieve adequate enrolment given the
sample size needed. Patients who are interested in par-
ticipating will receive a patient information letter and an
informed consent form (documents available from CV
on request). The information letter includes a statement
that a decision not to participate in the study will not
affect subsequent care. The coordinating investigator
and an independent physician are available to answer
any questions; their contact details are also provided.
The patient will be contacted by the study team 5 days
after receiving the information to discuss participation.
Patients will only be included in the study after written
informed consent has been obtained.
Data storage and confidentiality
All patient data will remain conﬁdential and will not be
shared outside the research team. Unique participant
identiﬁers will be used to collect the data (except the
informed consent form) and for entering data in a com-
puterised database for the purposes of analysis. The
identiﬁcation code is kept separate and will only be
accessible to the registered investigators. The investiga-
tors will safely store the informed consent forms
together with the identiﬁcation code (linking patient
identiﬁers and personal details) for 15 years and will
store the anonymised questionnaires (using participant
codes as identiﬁers) separately for 15 years. The hand-
ling of the personal data will be carried out in compli-
ance with the study protocol and the Dutch Personal
Data Protection Act.
Incentives
The ephedrine and placebo tablets taken during the
n-of-1 trial will be provided by the sponsor at no cost to
the patient. A patient undergoing treatment with ephe-
drine outside of this trial may have to pay or apply for
reimbursement of the tablets through a leniency
measure of the health insurance provider. Travel costs
made by participants for hospital visits will be
reimbursed.
Trial-related injury
The sponsor/investigator has obtained liability and clin-
ical trial insurance which is in accordance with article 7
of the Dutch Medical Research Involving Human
Subjects Act and the Measure regarding Compulsory
Insurance for Clinical Research in Humans 2003, which
provides cover for damage to research participants
through injury or death caused by the study.
Dissemination of results
All patients will receive the results of their individual
n-of-1 trials as per protocol (see ‘Analysis’ section). At
the end of the study, the study team will ﬁnalise a report
on the study. This report will be discussed with members
of regulatory organisations involved in market approval
and reimbursement of treatment. In addition, a lay
summary of the overall ﬁndings of the study will be
made available to the study participants. Anonymised
results of the study will be published in a peer-reviewed
journal, and will be presented at academic meetings and
6 Vrinten C, et al. BMJ Open 2015;5:e007863. doi:10.1136/bmjopen-2015-007863
Open Access
scientiﬁc conferences. Only the registered investigators
will have access to the individual patient data. Eligibility
for authorship shall be in accordance with the ICMJE
recommendations for authorship.
DISCUSSION
This series of randomised, controlled, double-blind
n-of-1 trials with open-label extension phase will evaluate
the effect of add-on treatment with ephedrine on
Table 1 WHO Trial Registration Data Set
Data category Information
Primary registry and trial
identifying number
EUCTR2014-001355-23-NL
Date of registration in primary
registry
27 March 2014
Secondary identifiers 40960
Source(s) of monetary or
material support
The Netherlands Organisation for Health Research and Development (ZonMW), grant
number 1520020301
Primary sponsor Leiden University Medical Center
Secondary sponsor(s) None
Contact for public queries Ephedrine study contact
Leiden University Medical Center
Albinusdreef 2
2333 ZA Leiden
The Netherlands
Tel: (+31) 17 15 262 118
Email: myasthenie@lumc.nl
Contact for scientific queries Ephedrine study contact
Leiden University Medical Center
Albinusdreef 2
2333 ZA Leiden
The Netherlands
Tel: (+31) 17 15 262 118
Email: myasthenie@lumc.nl
Public title Ephedrine as add-on therapy for patients with MG
Scientific title Ephedrine as add-on therapy for patients with MG
Country of recruitment Netherlands
Condition studied MG
Intervention(s) Active comparator: Ephedrine hydrochloride. Placebo comparator
Key inclusion and exclusion
criteria
Ages eligible for study: ≥18 years
Sexes eligible for study: both
Inclusion criteria: Adult patient with generalised MG for whom treatment with
pyridostigmine, either alone or in combination with low-dose prednisone or other
immunosuppressive drugs, does not adequately improve symptoms
Exclusion criteria: purely ocular myasthenia, ephedrine is contraindicated or was not
tolerated in the past, reliance on medium-to-high dose prednisone, intravenous
immunoglobulin, or plasma exchange therapy, myasthenic crisis in past 3 months,
thymectomy in past 6 months or scheduled, inability to comply with study procedures or
give informed consent
Study type Interventional
Controlled: yes, placebo
Allocation: randomised
Intervention model: multiple crossover assignment
Masking: double blind
Followed by optional open-label extension phase
Date of first enrolment 7 October 2014
Target sample size 4
Recruitment status Complete as of 29 December 2014
Primary outcome(s) Add-on effect of ephedrine on muscle strength/endurance as measured by the QMG score
for all patients enrolled
Key secondary outcomes Add-on effect of ephedrine for individual patients; feasibility of a larger series of n-of-1
trials, including patients’ and physicians’ experiences with the current trial; changes in
secondary outcomes measures including the MG-Composite and MG-ADL; long-term
effects of ephedrine (open-label extension study only); adverse effects of ephedrine
MG, myasthenia gravis; MG-ADL, MG-Activities of Daily Living; QMG, Quantitative Myasthenia Gravis.
Vrinten C, et al. BMJ Open 2015;5:e007863. doi:10.1136/bmjopen-2015-007863 7
Open Access
muscle strength and endurance in patients with general-
ised, autoimmune MG. Series of n-of-1 trials can be used
to determine population treatment effectiveness as well
as treatment effects in individual patients. N-of-1 trials
may be particularly valuable to explore population treat-
ment effects in patients with rare diseases, where
parallel-group RCTs may be unfeasible due to small
patient numbers.27 28
A limiting factor to the widespread use of series of
n-of-1 trials, however, is the requirement for a stable
disease course and for symptomatic, short-acting nature
of the investigational treatment due to the crossover
nature of the trial.43 Generalisability of the treatment
effect to the entire population may also be limited if
there is substantial heterogeneity in the study population
treatment effect, especially if the sample size is small.
Despite these limitations, data from the current series
of n-of-1 trials will be pooled to obtain a population
treatment effect estimate, and will be used to facilitate
regulatory innovation in two ways. First, the Dutch
National Health Care Institute (NHCI) is in the process
of implementing a ‘feasible information trajectory’ to
obtain ﬁtting evidence in situations where classic
(group-)RCTs are not feasible.44 A workgroup of the
NHCI will evaluate to what extent this study demon-
strates that an n-of-1 trial design is suitable to generate
evidence for reimbursement decisions. Second, based
on the results of this trial, a workgroup of the Dutch
Medicines Evaluation Board (MEB) will discuss scientiﬁc
regulatory questions which should be clariﬁed before
evidence from pooled n-of-1 trials could be used in a
request for marketing authorisation. Furthermore, tai-
lored implementation strategies, such as lectures and
seminars, will be used to stimulate a range of stake-
holders in the ﬁeld of rare diseases to consider further
development and use of n-of-1 trials.
Finally, we would like to invite clinicians and researchers
in other hospitals to contact the study team if they are con-
sidering using (a similar version of) the current study
protocol to conduct their own n-of-1 trials for add-on treat-
ment with ephedrine in patients with generalised MG.
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